Literature DB >> 18787351

Trisomy 22 as the sole abnormality is an important marker for the diagnosis of acute myeloid leukemia with inversion 16.

Wei Xu1, Hui-Fen Zhou, Lei Fan, Si-Xuan Qian, Li-Juan Chen, Hai-Rong Qiu, Su-Jiang Zhang, Jian-Yong Li.   

Abstract

BACKGROUND: The inversion of chromosome 16 (inv(16) (p13q22)) and the related t(16;16)(p13;q22) are chromosomal aberrations observed in approximately 10% of de novo acute myeloid leukemia (AML), mostly classified as M4Eo subtype, and associated with a relatively favorable outcome. However, it is a cryptic rearrangement and often difficult to recognize in conventional cytogenetics (CC). Trisomy 22 is an uncommon karyotypic aberration in AML and is often associated with inv(16)(p13q22). The aim of this study was to explore the value of trisomy 22 in the diagnosis of AML with inv(16). PATIENTS AND METHODS: Dual-color interphase fluorescence in situ hybridization (FISH) was performed in 19 AML cases with trisomy 22 abnormality shown by R-banding CC. The probe was a two-color break-apart probe for CBFbeta on the centromeric side and the telomeric side.
RESULTS: R-banding CC did not reveal inv(16) in any of the 19 AML with trisomy 22, but FISH analysis showed inv(16) in 11 cases and del(16)(q22) in 1 case. Among the 11 cases with inv(16), 9 showed trisomy 22 as the sole abnormality, 1 was complicated by trisomy 8, and 1 was del(16)(q22).
CONCLUSION: This study further confirmed that trisomy 22 as the sole abnormality can be regarded as an important marker for inv(16) in AML. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18787351     DOI: 10.1159/000141917

Source DB:  PubMed          Journal:  Onkologie        ISSN: 0378-584X


  1 in total

1.  Distinctive microRNA signature is associated with the diagnosis and prognosis of acute leukemia.

Authors:  Yuan-Dong Zhu; Li Wang; Chao Sun; Lei Fan; Dan-Xia Zhu; Cheng Fang; Yin-Hua Wang; Zhi-Jian Zou; Su-Jiang Zhang; Jian-Yong Li; Wei Xu
Journal:  Med Oncol       Date:  2011-12-31       Impact factor: 3.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.